NCT03364725

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Id Care · Academic / Other
• Sex: All
• Age: 18 Years – 30 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of Hepatitis C virus in study participants.

Detailed description

To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of Hepatitis C virus in study participants. Primary objective: 1\. Cure rates (SVR-12, HCV plasma RNA not quantifiable 12 weeks after last dose of treatment) of HCV in 30 recently identified PWIDS under 30 years old Secondary objectives: 1. Rate of sobriety maintenance for 1 year after enrollment 2. Re-infection rate with HCV over 1 year after enrollment 3. Re-admission rates for detox 4. Cravings

Conditions

• Hepatitis C
• Addict Heroin

Interventions

Type	Name	Description
DRUG	Glecaprevir-pibrentasvir	Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.

Timeline

• Start date: 2018-01-15
• Primary completion: 2018-09-01
• Completion: 2019-03-01
• First posted: 2017-12-07
• Last updated: 2017-12-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study